Working... Menu

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02006043
Recruitment Status : Unknown
Verified July 2015 by Li Zhang, Sun Yat-sen University.
Recruitment status was:  Recruiting
First Posted : December 9, 2013
Last Update Posted : July 3, 2015
Information provided by (Responsible Party):
Li Zhang, Sun Yat-sen University

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : December 2016
  Study Completion Date : No date given